Home  »  Finance   »  Why Gilead Sciences Inc. (NASDAQ: GILD) Stock Migh...

Why Gilead Sciences Inc. (NASDAQ: GILD) Stock Might Be A Good Investment

Gilead Sciences Inc. (NASDAQ:GILD) traded at $85.71 at last check on Tuesday, November 22, made an upward move of 1.62% on its previous day’s price.

Looking at the stock we see that its previous close was $84.35 and the beta (5Y monthly) reads 0.33 with the day’s price range being $83.64 – $85.17. The company has a trailing 12-month PE ratio of 31.90. In terms of its 52-week price range, GILD has a high of $85.17 and a low of $57.17. The company’s stock has gained about 24.43% over that past 30 days.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report

Sponsored

Gilead Sciences Inc. has a market cap of $105.80 billion and is expected to release its quarterly earnings report on Jan 30, 2023 – Feb 03, 2023. With its Forward Dividend at 2.92 and a yield of 3.46%, the company’s investors could be anxious for the GILD stock to gain ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of $1.39, with the EPS growth for the year raised at $6.54 for 2022 and $6.47 for next year. These figures represent -10.20% and -1.10% growth in EPS for the two years respectively.

Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $6.35 billion, with a low of $6.07 billion and a high of $6.72 billion. The median projection represents growth adding up to -12.40% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2022 is expected to hit $25.26 billion, or -7.50% down from figures reported last year.

There have been 2 upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the GILD stock, short term indicators assign the stock an average of 100% Buy, while medium term indicators assign it an average of 100% Buy. Long term indicators on average place the stock in the category of 100% Buy.

Based on estimates by 30 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 17 have rated the Gilead Sciences Inc. (GILD) stock as a Hold, while 13 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Overweight and investors could take advantage and scoop up stock of the company.

Looking further, we note that the PEG ratio for the GILD stock currently stands at 18.41, and the most recent price level today is 7.40% off its SMA20 and 20.93% from its 50-day simple moving average. The RSI (14) is pointing at 82.19 while the volatility over the past week is 1.58% and jumps to 2.62% over the past one month. The beta value is 0.45, while the average true range (ATR) is currently pointing at 1.96. The average price target for the stock over the next 12 months is $81.47, with the estimates having a low of $63.00 and a high of $96.00. These price ends are 26.5% and -12.01% off the today’s price level respectively, although investors could be excited at the prospect of a 3.16% if the GILD share price touches on the median price of $83.00.

Let’s briefly compare Gilead Sciences Inc. (GILD) stock to its peers. We find that today’s price change of 1.62% and 22.80% over the past 12 months for GILD competes that of Johnson & Johnson (JNJ), which has seen its stock price rise 0.37% in the latest trading session and is 8.03% over the last one year. Another of its peers Pfizer Inc. (PFE) has gained 1.98% today, and was -5.16% down over the past year, while Abbott Laboratories (ABT) is also up 0.20% yet, while its price remains in the red at -18.10% over the same period. Gilead Sciences Inc. has a P/E ratio of 31.90 compared to Johnson & Johnson’s 24.50 and Pfizer Inc.’s 9.14. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 0.72% and 0.82%, respectively, in early deals.

Coming back to Gilead Sciences Inc. (NASDAQ:GILD), we note that the average 3-month trading volume was 8.10 million, while that of the preceding 10-day period stands at 8.09 million. Current shares outstanding are 1.25 billion.

The insiders hold 0.09% of the company’s shares while institutions hold 83.00%. The data shows that short shares as of Oct 13, 2022, stood at 16.47 million at a short ratio of 2.19. This represents a 1.31% short interest in shares outstanding on Oct 13, 2022. Shares short fall in October from the previous month at 16.69 million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock 16.17% up in year-to-date price movement.

Leave a Comment

Your email address will not be published. Required fields are marked *

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]